Funding

Galvanize Therapeutics Secures $130M in Series D Financing

Nov 19, 2026 | By Devin Jacobs

Galvanize Therapeutics Secures $130M in Series D Financing

SUMMARY

  • Galvanize Therapeutics raised $130 million.
  • It will use the funds to develop new treatments.
  • It develops technology to treat cancer.

Galvanize Therapeutics, a Redwood City, California-based medical technology company developing pulsed electric field (PEF) treatments for cancer, and chronic diseases, has raised $130 million in a Series D financing round led by HealthQuest Capital.

The round included new investors Olympus Innovation Ventures and Braidwell, along with existing investors Sofinnova Partners, Norwest, Elevage Medical Technologies, Ally Bridge Group, Perceptive Advisors, Janus Henderson Investors, Longaeva Partners, Fidelity Management & Research Company and T. Rowe Price Associates.

The company will use the funding to expand its Aliya platform, generate more clinical evidence, advance its RheOx therapy for chronic bronchitis and develop next-generation PEF products.

What is Galvanize Therapeutics?

Galvanize Therapeutics develops pulsed electric field (PEF) technology for treating cancer, and chronic lung diseases.

Read More:Pedestal AI Raises $4.7M in Seed Funding Led by Eclipse

PEF technology uses controlled electrical pulses to affect targeted cells and tissues. The companys platform is designed to use these biological effects for medical treatments.

Its Aliya platform is focused on oncology applications, while RheOx is being developed as a treatment for chronic bronchitis.

Galvanize works with physicians, and healthcare providers to bring its technologies into clinical practice. It is also conducting research to understand the safety, effectiveness, and potential applications of PEF treatments.

About Galvanize Therapeutics

How Much Funding Has Galvanize Therapeutics Raised?

Galvanize Therapeutics has raised $130 million in its Series D financing round. The company has not disclosed it's total funding raised across all previous rounds.

Who Invested in Galvanize Therapeutics’ Series D Round?

The Series D round was led by HealthQuest Capital.

New participating investors included:

  • Olympus Innovation Ventures
  • Braidwell

Existing investors also participated, including Sofinnova Partners, Norwest, Elevage Medical Technologies, Ally Bridge Group, Perceptive Advisors, Janus Henderson Investors, Longaeva Partners, Fidelity Management & Research Company, and T. Rowe Price Associates.

Following the investment, Garheng Kong, MD, PhD, Founder and Managing Partner of HealthQuest Capital, will join Galvanize Therapeutics' Board of Directors.

Why the Funding Matters

Galvanize Therapeutics will use the funding to support the commercial expansion of its Aliya PEF platform, and strengthen its clinical research programme.

The company also plans to advance RheOx therapy for chronic bronchitis and develop next-generation PEF products and platforms.

The investment will support its efforts to expand physician adoption and build further clinical evidence for its technology across oncology and chronic disease applications.

Galvanize Therapeutics funding

Who founded Galvanize Therapeutics?

Galvanize Therapeutics was founded in 2015. The company has not disclosed its founders in the funding announcement.

It is headquartered in Redwood City, California, and is commercialising its Aliya PEF platform in the United States.

"This financing marks an important inflection point for Galvanize," said Doug Godshall, Chairman, and Chief Executive Officer of Galvanize Therapeutics. "We've built a strong foundation with Aliya, demonstrating the potential of our PEF technology through growing physician adoption, commercial execution and an expanding body of clinical evidence.

Market and Business Growth

Galvanize Therapeutics has made progress across its commercial, clinical, and technology programmes.

The company has received FDA clearance and launched its next-generation Aliya EX Generator. Its Aliya PEF technology has also surpassed 4000 procedures performed.

On the clinical research side, Galvanize has enrolled more than 300 patients in its PROPEL registry. Its technology is also supported by more than 40 peer reviewed publications examining PEF mechanisms clinical outcomes, and potential applications.

These milestones reflect the company's progress in expanding the use of PEF technology across oncology and chronic disease treatment.

What Happens Next?

Galvanize Therapeutics plans to continue expanding its Aliya platform, and generating clinical evidence to support its medical applications.

It will also advance RheOx therapy for chronic bronchitis and work on developing new PEF products and platforms.

Read More:Aarden Raises $8M in Funding Led by Overture Ventures

Recommended Stories for You